Mount Sinai Researchers Identify Mechanism Linking APOE4 to Alzheimer's Damage
Researchers at Mount Sinai have identified a biological mechanism linking the APOE4 genetic risk factor to brain blood vessel damage and amyloid accumulation, offering new insights for Alzheimer's research.
A significant development in Alzheimer's research has emerged as scientists from the Icahn School of Medicine at Mount Sinai in New York identified a biological mechanism explaining how a major genetic risk factor damages brain blood vessels and promotes the accumulation of harmful proteins.
The Gene Increasing Alzheimer's Risk
At the center of the research is the APOE4 gene variant, widely recognized as the most significant genetic risk factor for common Alzheimer's disease. While carrying this genetic variant has long been linked to an increased risk of developing the condition, the exact mechanisms through which it harms the brain remained under investigation. In the new study, researchers discovered that APOE4 can cause cells supporting small brain blood vessels to transform into cells that promote scar tissue formation. This process leads to scarring around blood vessels and an increased accumulation of amyloid, a protein whose buildup is associated with Alzheimer's disease.
Researchers Successfully Delayed the Process
One of the significant findings in the study is the identification of a biological pathway called TGF-beta, which is involved in the scarring process. When researchers blocked its activity in experimental models, they successfully reduced scarring and amyloid accumulation around the blood vessels. These findings were also replicated in older mice carrying the APOE4 genetic variant. In a separate study, researchers utilized 3D human brain tissue developed from stem cells, discovering that APOE4 can lead to cholesterol accumulation in supporting brain cells, thereby impairing their ability to break down and clear harmful proteins.
Toward a New Treatment for Alzheimer's?
Not yet. Despite the encouraging results, the studies focus on biological mechanisms and pre-clinical experiments, and they have not tested a treatment proven effective in human Alzheimer's patients. However, identifying the processes involved in vascular damage and protein clearance may open new research directions. Future studies will be required to determine whether these mechanisms can be safely targeted in humans and whether such intervention can slow disease progression.
